Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Short Communication, Mol Med Ther Vol: 1 Issue: 1
Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease
| Tessa M. Simone and Paul J. Higgins* |
| Center for Cell Biology & Cancer Research, Albany Medical College, Albany, New York 12208, USA |
| Corresponding author : Paul J. Higgins Center for Cell Biology & Cancer Research, Albany Medical College, 47 New Scotland Avenue, Albany, New York 12208, USA Tel: 518-262-5168; Fax: 518-262-5669 E-mail: higginp@mail.amc.edu |
| Received: July 16, 2012 Accepted: August 02, 2012 Published: August 05, 2012 |
| Citation: Simone TM, Higgins PJ (2012) Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease. Mol Med Ther 1:1 doi:10.4172/2324-8769.1000102 |
Abstract
Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease
Plasminogen activator inhibitor-1 (PAI-1; SERPINE1) is the major physiologic regulator of the plasmin-based pericellular proteolytic cascade, a modulator of vascular smooth muscle cell (VSMC) migration and a causative factor in cardiovascular disease and restenosis, particularly in the context of increased vessel transforming growth factor- β1 (TGF-β1) levels. PAI-1 limits conversion of plasminogen to plasmin (and, thereby, fibrin degradation) by inhibiting its protease targets urokinase and tissuetype plasminogen activators (uPA, tPA).